2-substituted-1,3-cyclohexanedione derivatives act as buffering molecules for non-aqueous solutions.
Growing demand for vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, therapeutic recombinant protein, and living cells used in cell therapy are driving the global biopharma buffer market. Maintaining product and reagent stability has long been an issue for the pharmaceutical and drug development industry. Buffers are used both for upstream and downstream development and production processes and a lack of a suitable buffer can result in unexpected manufacturing delays, product/reagent instability, and major economic losses. However, no molecules that neutralize both acids and bases in organic solvents or that have buffering functions in non-aqueous solutions to maintain conditions suitable for chemical reactions have been commonly used. Here, we present a promising buffer developed by a group of researchers led by Prof. Fujie Tanaka. The suggested technology for non-aqueous solution media proposes a simple solution to some of the production challenges with the potential to dramatically cut losses and increase derived financial benefits from existing processes.
Essentially, Prof. Tanaka has developed a molecule having a buffer function in a non-aqueous solution. The trace presence of acid or base often causes isomerization, decomposition, and/or racemization of molecules of interest. The addition of the developed buffering molecule or its resin-conjugated version in storage solutions of molecules of interest can prevent decomposition, isomerization, and/or racemization caused by both acids and bases.
- Drug Discovery
- Chemical Storage
- Non-Aqueous Buffer Function
- Simple Production
- Chemical Reaction Control